Headlands Technologies LLC Purchases Shares of 1,291 Illumina, Inc. (NASDAQ:ILMN)

Headlands Technologies LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMNFree Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,291 shares of the life sciences company’s stock, valued at approximately $177,000.

Several other hedge funds have also recently modified their holdings of ILMN. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Illumina in the 3rd quarter worth approximately $30,000. State of Wyoming purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $32,000. Quent Capital LLC lifted its position in shares of Illumina by 71.2% in the 3rd quarter. Quent Capital LLC now owns 250 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 104 shares during the period. ST Germain D J Co. Inc. purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $36,000. Finally, Riverview Trust Co lifted its position in shares of Illumina by 203.5% in the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Hedge funds and other institutional investors own 92.17% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ILMN. Guggenheim began coverage on shares of Illumina in a research report on Thursday, December 14th. They issued a “buy” rating and a $155.00 price target for the company. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday. Canaccord Genuity Group lowered shares of Illumina from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $210.00 to $120.00 in a research note on Friday, November 10th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, Wolfe Research initiated coverage on shares of Illumina in a research note on Wednesday, December 13th. They set an “outperform” rating and a $175.00 price objective for the company. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $166.95.

Get Our Latest Stock Report on ILMN

Illumina Trading Down 3.8 %

Shares of Illumina stock opened at $137.84 on Friday. The firm has a fifty day moving average price of $135.24 and a 200 day moving average price of $137.96. The stock has a market cap of $21.89 billion, a PE ratio of -18.78, a price-to-earnings-growth ratio of 24.83 and a beta of 1.22. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $238.55. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.69 and a quick ratio of 1.28.

Illumina (NASDAQ:ILMNGet Free Report) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.15% and a negative net margin of 25.78%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS. Equities research analysts predict that Illumina, Inc. will post 1.03 earnings per share for the current year.

Illumina Company Profile

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Recommended Stories

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.